|
|
|
| The clinical analyzing of treatment primary nephrotic syndrome by tacrolimus |
| WEI Jian-bo NING Fang-fang LU Qin-yan |
| Department of Nephrology,the Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan 511518,China |
|
|
|
|
Abstract ObjectiveTo explore the clinical effects of treatment primary nephrotic syndrome by tacrolimus.Methods30 cases clinical data of primary nephrotic syndrome patients in our hospital department of nephrology from February 2011 to March 2015 were selected,and divided into two groups by different treatment methods,the control group（cytoxan compared with prednisone acetate treatment）15 cases and the Tacrolimus group （prednisone acetate compared with tacrolimus treatment）15 cases.The serum albumin,creatinine,cholesterol,triglyceride,urine protein quantitation of two groups primary nephrotic syndrome patients before treatment and after treatment 6 moths were compared,clinical curative effect of two groups primary nephrotic syndrome patients were compared.ResultsThe serum albumin,creatinine, cholesterol,triglyceride,urine protein quantitation of two groups primary nephrotic syndrome patients before treatment were no significant difference(P＞0.05),the serum albumin of control group and Tacrolimus group after treatment 6 moths were higher than before treatment;the creatinine,cholesterol,triglyceride,urine protein quantitation were lower than before treatment;the serum albumin of Tacrolimus group after treatment 6 moths was higher than that of control group;the creatinine,cholesterol,triglyceride,urine protein quantitation were lower than that of control group;the remission rate of treatment group was higher than that of control group,the differences were significant(χ2=7.65，P＜0.05).ConclusionThe clinical symptoms of treatment primary nephrotic syndrome by tacrolimus is obviously,remission rate is high,it is worth to be used.
|
|
|
|
|
|
| [1] |
Cross NB，Webster AC，Mas son P，et al.Antihypertensives forkidney transplantrecipients：systematic review and metaanalysis of randomized controlled trials[J].Transplantation，2009，88（1）：7-18．
|
| [2] |
侯终君.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床效果[J].中国医药导报，2014，31（9）：69-72.
|
| [3] |
Leroy S，Isapof A，Fargue S，et al.Tacrolimus nephrotoxicity：bew are of the association of diarrhea，drug interaction and pharmacogenetics[J].Pediatr Nephrol，2010，25（5）：965-969．
|
| [4] |
龚峰.他克莫司联合小剂量激素治疗儿童激素抵抗型肾病综合征的临床研究[J].中国医药导报，2012，9（26）：78-80.
|
| [6] |
李杰，刘铁.他克莫司联合小剂量糖皮质激素治疗肾病综合征疗效观察[J].陕西医学杂志，2015，35（7）：900-901．
|
| [8] |
周优丽，沈增晖，姚云，等.他克莫司联合激素对儿童激素耐药难治性肾病综合征的疗效研究[J].儿科药学杂志，2016，22（3）：21-23.
|
| [10] |
罗群，蔡珂丹，高燕红，等.他克莫司联合激素治疗难治性特发性膜性肾病[J].中华全科医学，2014，12（4）：522-524．
|
| [5] |
Kang SY，Sohn KH，Lee JO，et al.Intravenous tacrolimus and cyclosporine induced anaphylaxis：what is next[J].Asia Pac Allergy，2015，5（3）：181-186．
|
| [7] |
Ueda Y，Uemoto S.Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation[J].Transpl Int，2016，29（1）：119-121.
|
| [9] |
Hoorn EJ，Walsh SB，Mccormick JA，et al.The calcineurin in-hibitor tacrolimus activates the renal sodium chloride cotrans-porter to cause hypertension[J].Nat Med，2011，17 （10）：1304-1309．
|
| [11] |
Aydogan M，Yologlu N，Gacar G，et al.Successful rapid rituximab desensitization in an adolescent patientwith nephrotic syndrome：increase in number of Treg cells after desensitization[J].J Allergy Clin Immunol，2013，132（2）：478-480．
|
| [12] |
叶馄.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床评估[J].中华医学杂志，2013，29（9）：1500-1502.
|
| [13] |
杨敏，魏传梅，刘乃国.CYP3A5基因多态性对膜性肾病患者他克莫司初始剂量的预测价值[J].中华肾脏病杂志，2015，31（10）：736-742.
|
| [14] |
熊清玓，徐媖.大黄结合他克莫司对肾病综合征患者血药浓度的影响观察[J].江西中医药，2016，47（4）：49.
|
| [15] |
Wang Y，Bu J，Zhang Q，et al.Expression pattern of aquaporins in patients with primary nephrotic syndrome with edema[J].Mol Med Rep，2015，11（8）：112-116.
|
| [16] |
杨敏，魏传梅，刘乃国.CYP3A5基因多态性对膜性肾病患者他克莫司初始剂量的预测价值[J].中华肾脏病杂志，2015，31（10）：736-742.
|
|
|
|
